AUM302, a novel triple kinase PIM/PI3K/mTOR inhibitor, is a potent in vitro pancreatic cancer growth inhibitor
PLOS ONE · 2023
DOI: 10.1371/journal.pone.0294065 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Komala Ingle und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Renaissance School of Medicine at Stony Brook University, Stony Brook, New York, United States of America. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Antineoplastic Agents, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 106 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Pancreatic cancer is one of the leading causes of cancer deaths, with pancreatic ductal adenocarcinoma (PDAC) being the most common subtype. Advanced stage diagnosis of PDAC is common, causing limited treatment opportunities. Gemcitabine is a frequently used chemotherapeutic agent which can be used as a monotherapy or in combination. However, tumors often develop resistance to gemcitabine. Previous studies show that the proto-oncogene PIM kinases (PIM1 and PIM3) are upregulated in PDAC compared to matched normal tissue and are related to chemoresistance and PDAC cell growth. The PIM kinases are also involved in the PI3K/AKT/mTOR pathway to promote cell survival. In this study, we evaluate the effect of the novel multikinase PIM/PI3K/mTOR inhibitor, AUM302, and commercially available PIM inhibitor, TP-3654. Using five human PDAC cell lines, we found AUM302 to be a potent inhibitor of cell proliferation, cell viability, cell cycle progression, and phosphoprotein expression, while TP-3654 was less effective. Significantly, AUM302 had a strong impact on the viability of gemcitabine-resistant PDAC cells. Taken together, these results demonstrate that AUM302 exhibits antitumor activity in human PDAC cells and thus has the potential to be an effective drug for PDAC therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Renaissance School of Medicine at Stony Brook University, Stony Brook, New York, United States of America.
- Department of Pharmacology, School of Medicine, the University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
- Department of Biological & Biomedical Sciences, College of Health & Sciences, North Carolina Central University, Durham, North Carolina, United States of America.
ORCID-Profile: Agnieszka B Bialkowska
Förderung
- NIDDK NIH HHS
- National Institutes of Health
Zitieren
APA
Ingle, K., LaComb, J. F., Graves, L. M., Baines, A. T., & Bialkowska, A. B. (2023). AUM302, a novel triple kinase PIM/PI3K/mTOR inhibitor, is a potent in vitro pancreatic cancer growth inhibitor. PLOS ONE. https://doi.org/10.1371/journal.pone.0294065
Vancouver
Ingle K, LaComb JF, Graves LM, Baines AT, Bialkowska AB. AUM302, a novel triple kinase PIM/PI3K/mTOR inhibitor, is a potent in vitro pancreatic cancer growth inhibitor. PLOS ONE. 2023. doi:10.1371/journal.pone.0294065
BibTeX
@article{Ingle2023,
author = {Ingle, Komala and LaComb, Joseph F and Graves, Lee M and Baines, Antonio T and Bialkowska, Agnieszka B},
title = {AUM302, a novel triple kinase PIM/PI3K/mTOR inhibitor, is a potent in vitro pancreatic cancer growth inhibitor},
journal = {PLOS ONE},
year = {2023},
doi = {10.1371/journal.pone.0294065}
}
EUVIMED